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Functional contributions of carbohydrate on
AidS Virus Glycoprotein
Elizabeth Stansell and Ronald C. Desrosiers*
New England Primate Research Center, Harvard Medical School, Southborough, 
Massachusetts 
Envelope glycoprotein spikes on the surface of the human immunodeficiency virus (HIV†)
are used by the virus to bind to cellular receptors to gain entry into target cells. As such, the
envelope spikes are the targets of antibodies that can neutralize viral infectivity. Fifty percent
or more of the mass of the viral-encoded surface glycoprotein of HIV, and of its close mon-
key relative simian immunodeficiency virus (SIV), is actually carbohydrate; it is one of the
most heavily glycosylated proteins that can be found in mammals. It has been clearly
demonstrated that one of the functions of this carbohydrate is to shield viral epitopes that
would otherwise be the direct target of antibodies that could neutralize viral infection. In ad-
dition, it is now generally accepted that the carbohydrate on the viral envelope glycoprotein
is recognized by multiple cellular lectins of the host lymphoreticular system, and these in-
teractions play a role in the dissemination of virus within the host as well as the release of
modulatory cytokines. Our work recently demonstrated fundamental differences in the com-
position of the carbohydrate on HIV type 1, the cause of the AIDS pandemic, versus the
SIV in the sooty mangabey monkey, a natural host that does not develop disease from its
infection. we now speculate that this fundamental difference in carbohydrate composition
reflects evolutionary pressures on both virus and host. Furthermore, carbohydrate compo-
sition on the virus and genetic differences in carbohydrate-sensing proteins of the host could
be critically important for the generalized lymphoid activation that characterizes the acquired
immunodeficiency syndrome (AIDS).
introduction
Incorporation of the envelope protein
(Env) spike is essential for the infectivity of
HIV and SIV. Env is synthesized from a
singly spliced viral mRNA and directed to
the secretory pathway of the infected cell by
an amino terminal signal peptide of 25 amino
acids [1]. The Env precursor protein, gp160,
oligomerizes into trimers through interac-
tions of the transmembrane protein domain
[2,3,4]. Then, cellular furin or furin-like pro-
teases cleave the oligomerized gp160s into
the surface subunit (gp120) and the trans-
membrane protein (gp41), which are nonco-
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plex [5,6]. In most cell types, Env is trafficked
to the plasma membrane, where it is incorpo-
rated into virus particles [7]. For macrophage
cells, Env is incorporated into virus particles
largely at the multi-vesicular body [8]. Virus is
contained in the macrophage multivesicular
body prior to the fusion of this compartment
with the plasma membrane when infectious
virions are released [8]. 
The Envs of HIV and SIV are heavily
modified with carbohydrate. The attachment
of N-linked carbohydrate is initiated when
the carbohydrate core oligosaccharide (two
N-acetylglucosamine,  nine  mannose,  and
three glucose) is transferred en blocto the as-
paragine of the N-linked consensus sequence
N-X-S or N-X-T, where X is any amino acid
except a proline [9-13]. Then, the glucose is
removed to form high-mannose carbohydrate
chains that terminate in mannose [12]. High-
mannose  carbohydrate  may  be  further
processed into complex or hybrid oligosac-
charides [14]. Fully processed complex car-
bohydrate  chains  terminate  in  galactose,
N-acetylglucosamine, sialic acid, or glucose
[15,16]. Hybrid carbohydrate chains have
one branch that terminates in mannose and
another branch that terminates in a sugar of
the complex type [17]. Therefore, at each oc-
cupied site, the N-linked carbohydrate chain
may be one of three types: high-mannose,
complex, or hybrid. 
In  addition  to  the  attachment  of  N-
linked carbohydrate, the Envs of HIV and
SIV also may be modified with O-linked car-
bohydrate in the secretory pathway of the in-
fected  cell.  This  type  of  carbohydrate
attachment, commonly referred to as mucin-
type [18], initiates with the covalent attach-
ment of N-acetylgalactosamine (GalNAc) to
the hydroxyl group of serine (Ser) and/or
threonine  (Thr)  to  form  the  Tn  antigen
[19,20]. There are no clear-cut rules that dis-
tinguish a glycosylated Ser or Thr from a
non-glycosylated Ser or Thr in the primary
protein sequence [18]. After the addition of
GalNAc, the carbohydrate chain may then be
elongated by the addition of galactose, N-
acetylglucosamine, and sialic acid in differ-
ent combinations and linkages [18,21]. The
Tn antigen, core 1, immature core 2, core 2,
and the sialylated versions are the most com-
mon mucin-type O-linked carbohydrate [22].
Function oF n-LinKEd 
cArBoHYdrAtE in ForMAtion
oF A FuSion-coMPEtEnt EnV
ProtEin coMPLEX
Initial observations of N-linked carbo-
hydrate contributing to the function of Env
were made in studies where virus made in
the presence of glucosidase inhibitors dis-
played  impaired  infectivity  compared  to
virus  made  in  the  absence  of  inhibitors
[23,24]. The inhibition of infectivity or syn-
cytium formation could be attributed to an
altered N-linked glycosylation pattern of
Env, a decreased cell surface expression of
the  mature  Env  glycoprotein,  and  a  de-
creased processing of the precursor gp160
into gp120 and gp41 compared to that of
Env from mock treated cells [25].
The effects of carbohydrate on folding,
processing, and efficient intracellular transport
of Env also were detected for viral variants
lacking a subset of N-linked glycans from ei-
ther gp120 or gp41 [26-29]. Li et al. identified
a subset of N-linked carbohydrate that was
important for proper folding of the CD4 bind-
ing pocket of gp120 [27]. Reitter et al. and
Pikora et al. noted a decreased processing
from “gp160” to “gp120” for mutants that
lack three sites in combination within gp120
[28,29]. Fenouillet and Jones reported that a
mutant precursor of Env that lacked three con-
served N-linked sites of HIV type 1 (HIV-1)
gp41 was deficient for transport resulting in a
deficient processing of gp160 [26].
The role of N-linked carbohydrate is
thus particularly important for the assembly
of a fusion-competent Env spike. After the
Env spike is assembled, enzymatic removal
of N-linked glycosylation does not affect the
functional conformation [30-35]. 
Function oF cArBoHYdrAtE in
SHiELdinG EPitoPES 
In a seminal paper, variants of patho-
genic  SIV  from  rhesus  macaque  (SIV-
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cosylation sites of gp120 were much better
at eliciting neutralizing antibodies and much
more sensitive targets for neutralization than
the parental SIVmac239 strain [36]. A vari-
ant of SIVmac239 that lacked five N-linked
sites in gp120 replicated normally in mon-
keys for the first two weeks [36]. Notably,
the infection was then controlled, at least in
part by neutralizing antibodies, at low or un-
detectable levels for more than two years
[36]. This study indicated that removal of
carbohydrate triggered an antibody response
that effectively controlled viral replication
and also provided evidence for the necessity
of an intact glycan shield to protect the virus
against the attack of the host immune system. 
The importance of an intact carbohy-
drate shield also was highlighted for HIV-1
in a report in which the glycosylation pat-
tern of viral escape variants was introduced
into two sensitive strains [37]. The addition
of multiple N-linked sites into both sensitive
strains was sufficient to acquire a neutral-
ization-resistant phenotype, thereby provid-
ing  evidence  of  a  continuously  evolving
glycan shield in HIV-1 [37].
Now, it is generally accepted that car-
bohydrate covers portions of antigenic sites
of the Env protein such that increased num-
bers of N-linked glycosylation sites in gp120
of HIV-1 and SIV are associated with an in-
creased  resistance  to  antibody-mediated
neutralization, while loss of N-linked sites
frequently results in virus that is more sus-
ceptible to antibody-mediated neutralization
[36,38-48]. Consistent with N-linked carbo-
hydrate  physically  hindering  antibody
recognition of epitopes that would otherwise
be the direct targets of neutralizing antibod-
ies, variants of SIVmac239 that lacked N-
linked  sites  in  gp120  or  gp41  elicited
antibodies with new specificities when com-
pared to antibodies from SIVmac239 sera
[49,50]. 
What about O-linked carbohydrate and
the carbohydrate shield? Chackerian et al.
beautifully demonstrated a role for O-linked
carbohydrate in shielding SIV from neutral-
ization by host antibodies [39]. Similarly, a
rhesus macaque that developed a neutraliz-
ing antibody response to SIVmac239 had an
escape variant that introduced a Thr into an
existing O-linked carbohydrate attachment
site [46,51]. 
HiV-1 GP120 cArBoHYdrAtE-
HoSt LEctin intErActionS 
The carbohydrate of HIV-1 and SIV
gp120 has been found to bind lectins on the
surface of dendritic cells, enhance the infec-
tion of HIV permissive cells, and modulate
the immune response. Geijtenbeek et al. el-
egantly showed that binding of HIV-1 gp120
to dendritic cell-specific intercellular adhe-
sion molecule-3-grabbing non-integrin (DC-
SIGN),  a  type  II  transmembrane  C-type
lectin with a single C-terminal carbohydrate
recognition domain [52], facilitated the in-
fection  of  HIV  permissive  T-cells  via  a
trans-infection pathway [53]. Virions bound
to macrophage cells expressing DC-SIGN
could trans-infect CD4+ T-cells four days
after capture, and this trans-infection could
be  blocked  by  an  antibody  to  DC-SIGN
[53]. DC-SIGN binds to HIV-1 gp120 via
carbohydrate since the removal of specific
glycans from gp120 decreased the capacity
of DC-SIGN to bind, which led to a de-
creased  efficiency  of  trans-infection  of
CD4+ T-cells [54].
HIV-1 gp120 carbohydrate functions
through binding DC-SIGN to activate cru-
cial  components  of  the  immune  system.
Binding of HIV-1 gp120 to DC-SIGN in-
duced Raf-1 dependent phosphorylation of
the NF-B subunit p65 at Ser276 that re-
cruited  transcription-elongation  factor
pTEF-b to nascent transcripts for the syn-
thesis of full-length viral transcripts leading
to a productive infection of dendritic cells
[55]. Separately, binding of the high-man-
nose carbohydrate of gp120 to DC-SIGN
also induced signaling of the ERK pathway
in dendritic cells that resulted in the release
of IL-10, an immunosuppressive cytokine
that may contribute to the TH2 bias of the
anti-gp120 immune response [56,57,58].
Carbohydrate of HIV-1 binds to many
C-type lectins as well as other lectins of the
human immune system [59,60,61]. Another
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drate on gp120 is the soluble mannose bind-
ing lectin (MBL) [62]. MBL is a member of
the collagenous lectin (collectin) family of
proteins, large multimeric proteins that con-
sist of collagen and a Ca2+-dependent carbo-
hydrate-binding domain [63]. The collectins
are a part of the larger group of C-type lectins
[63]. In vitro, the mannose binding lectin in-
hibits  trans-infection  mediated  by
macrophage cells expressing DC-SIGN [64].
In vivo, the level of MBL in human sera
varies due to polymorphisms in the promoter
of the gene and point mutations within the
protein-coding region [65]. In some studies,
low levels of MBL have been associated with
an increased susceptibility to HIV-1 infection
and an increased progression of disease, sup-
porting the theory that either high or medium
levels of MBL are required for the control of
disease progression [65].
HiV-1 GP120 cArBoHYdrAtE And
tHErAPEutic LEctinS 
The lectin Cyanovirin-N (CV-N), an 11
Kda protein isolated from blue green algae,
directly targets carbohydrates on the Env of
HIV to block viral entry into cells [66]. In
2003, CV-N was applied in a gel to the rec-
tum  of  monkeys  to  effectively  protect
against infection of SHIV89.6, a virus that
is primarily SIV but expresses the Env of
HIV [67]. Subsequent to this proof of prin-
ciple experiment, interest in the use of CV-
N  in  human  trials  waned  due  to  safety
concerns. Suboptimal concentrations of CV-
N enhanced HIV infection of human pe-
ripheral blood mononuclear cells [68]. Also,
the process of cell division was stimulated
in the presence of CV-N [69]. Recently, a
similar lectin has been identified that re-
portedly does not have these negative side
effects [70], which may prove to be a thera-
peutic directed toward the carbohydrate of
HIV-1 Env.
cArBoHYdrAtE coMPoSition
oF tHE GP120S FroM HiV-1 And
SiV FroM SootY MAnGABEYS
(SiVSM) 
Recently, we have identified fundamen-
tal differences in both the N-linked and O-
linked carbohydrate composition for HIV-1
versus SIVsm [51,71]. We defined two N-
linked sites in the external surface glycopro-
tein  gp120  and  one  in  the  gp41
transmembrane glycoprotein whose mutation
imparted  high-level  resistance  to  the  in-
hibitory effects of the high-mannose carbo-
hydrate binding lectins GNA and HHA onto
cloned SIVmac239 [71]. This was in contrast
to selection of HIV-1, where the GNA and
HHA-resistant population lacked eight of 24
N-linked  sites  in  gp120  [72]. We  used  a
GNA-binding ELISA to show that assorted
HIV-1 and SIVcpz gp120s are consistently
and considerably higher in high-mannose
composition than assorted gp120s from SIV-
mac, SIVsm, and HIV type 2 (HIV-2) (Table
1) [71]. In a separate study, we identified an
O-linked carbohydrate attachment region in
the gp120 of SIVmac239, whose mutation
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Virus n-linked
High-mannose
carbohydrate
Host o-linked 
carbohydratea
Progression to
disease
HiV-1b
SiVcpzb
SiVsmc
SiVmacc
HiV-2c
human
chimpanzee
sooty mangabey
rhesus macaque
human
high
high
low
low
low
yes
+/-
no
yes
slow
no
no
yes
yes
yes
table 1. Description of the viral host, carbohydrate composition, and disease progression.
a. of the non- and mono-sialylated core 1 types.
b. Cross-species transmission of SIVcpz to humans is believed to be the source of HIV-1.
c. Cross-species transmission of SIVsm to rhesus macaques and to humans is thought to be the
source of SIVmac and HIV-2, respectively.imparted  high-level  resistance  to  the  in-
hibitory effects of jacalin, a lectin that binds
O-linked  carbohydrate,  onto  cloned  SIV-
mac239 [51]. Modification of the gp120 of
SIVmac239 with non- and mono-sialylated
core 1 carbohydrate was confirmed by mass
spectrometry [51]. Furthermore, using a ja-
calin-binding ELISA, we showed that as-
sorted  gp120s  from  SIVmac  and  SIVsm
were consistently modified with non- and
mono-sialylated core 1 mucin-type O-linked
carbohydrate  while  assorted  HIV-1  and
SIVcpz gp120s consistently lacked these ja-
calin-sensitive structures (Table 1) [51].
FundAMEntAL diFFErEncES oF
cArBoHYdrAtE coMPoSition
BEtWEEn HiV-1 And SiVSM And
intErActionS WitH LEctinS oF
tHE HoSt LYMPHorEticuLAr
SYStEM 
The best characterized interaction of the
carbohydrate of HIV and SIV Env is the bind-
ing to the host lectin DC-SIGN. DC-SIGN on
dendritic cells has been shown to mediate
trans-infection of permissive CD4+ T-cells
for HIV-1, HIV-2, SIVmac, SIVmne, and SIV
from African green monkeys [73,74,75]. In
trans-infection experiments, HIV-1 Env that
had a high high-mannose carbohydrate com-
position mediated the infection of CD4+ T-
cells seven times more than that of the low
high-mannose HIV-2 Env [74]. 
Interestingly,  even  though  the  DC-
SIGN of multiple species of monkeys have
been shown to mediate the trans-infection of
virus, no animal experiment has been re-
ported showing the contribution of trans-in-
fection  mediated  by  DC-SIGN  to  the
dissemination of virus in the host. This is
probably due to the multitude of lectins that
can  mediate  trans-infection.  In  rhesus
macaques, dendritic cells have been reported
to efficiently transmit primate lentiviruses
independently of DC-SIGN [76].
concLudinG rEMArKS
The carbohydrate of the HIV and SIV
Env functions in the proper folding and pro-
cessing of a fusion-competent Env spike,
functions to shield the virus from effective
antibody-mediated neutralization of infec-
tion, functions to bind host lectins to enhance
the infection of permissive cells, and func-
tions to trigger signaling pathways resulting
in both the productive infection of dendritic
cells and the release of immune modulatory
cytokines from dendritic cells. The newly
highlighted differences in the composition of
N-linked and O-linked carbohydrate on HIV-
1 gp120 versus SIVsm gp120 may result in
these  lentiviruses  engaging  differentially
with host lectins. The intriguing question
arises whether these differences in carbohy-
drate composition may modulate the interac-
tion of virus with the host such that humans
infected  with  HIV-1  progress  to  disease
while the majority of naturally infected sooty
mangabeys resist generalized lymphoid acti-
vation and disease progression despite high
levels  of  SIV  replication.  Determining
whether carbohydrate indeed plays a role in
mediating the activated state of the immune
response to HIV in humans, and if so, the
mechanism behind this activation, will be
critical in the development of therapeutics di-
rected toward the carbohydrate of Env. 
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